Paullones constitute a new family of benzazepinones with promising antitumoral properties. They were recently described as potent, ATP-competitive, inhibitors of the cell cycle regulating cyclin-dependent kinases (CDKs). We here report that paullones also act as very potent inhibitors of glycogen synthase kinase-3b (GSK-3b) (IC 50 : 4±80 nm) and the neuronal CDK5/p25 (IC 50 : 20±200 nm). These two enzymes are responsible for most of the hyperphosphorylation of the microtubule-binding protein tau, a feature observed in the brains of patients with Alzheimer's disease and other neurodegenerative`taupathies'. Alsterpaullone, the most active paullone, was demonstrated to act by competing with ATP for binding to GSK-3b. Alsterpaullone inhibits the phosphorylation of tau in vivo at sites which are typically phosphorylated by GSK-3b in Alzheimer's disease. Alsterpaullone also inhibits the CDK5/p25-dependent phosphorylation of DARPP-32 in mouse striatum slices in vitro. This dual specificity of paullones may turn these compounds into very useful tools for the study and possibly treatment of neurodegenerative and proliferative disorders.
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Phosphorylation on serine, threonine and tyrosine residues by protein kinases constitute one of most common mechanisms of post-translational modifications of proteins. Among the estimated 2000 human protein kinases, we are presently investigating the functions of two related families of kinases, the cyclin-dependent kinases (CDKs) and glycogen synthase kinases 3 (GSK-3) [1, 2] (see also http://www.sdsc.edu/kinases). CDKs play a key role in cell cycle regulation, centrosome duplication, transcription, muscular and neural functions and apoptosis (reviewed in [3±8]). GSK-3 is involved in the WNT signaling pathway [9] , cell cycle regulation [10, 11] , dorsoventral patterning during development [12, 13] , insulin action on glycogen synthesis [14, 15] , axonal outgrowth [16] , HIV-1 Tat-mediated neurotoxicity [17] , among others.
Neurofibrillary tangles are argyrophilic structures composed of paired helical filaments (PHF) which are observed in the human brain under many pathological conditions, such as Alzheimer's disease (AD), Down's syndrome and Pick's disease, among others. These structures were initially described in 1907 by Alois Alzheimer [18, 19] , but their major constituent was only identified in 1988 as a highly insoluble form of the microtubule-binding protein tau ( [20, 21] ; reviewed in [22±25]). All six tau isoforms, which derive from a single gene by alternate splicing, are hyperphosphorylated in PHF. Phosphorylation occurs on over 20 sites, mostly at Ser/Pro and Thr/ Pro sites. AD tau, but not normal tau, cross-reacts with phospho-specific antibodies directed against some of these sites. A number of protein kinases phosphorylate tau in vitro, but the most physiologically relevant appear to be GSK-3b (Tau protein kinase I), CDK5/p25 (Tau protein kinase II), cAMPdependent protein kinase (PKA) and casein kinase 1 (CK1) (reviewed in [23±26] ).
Cells transfected with GSK-3b [27] and mice expressing high levels of GSK-3b [28] show AD-specific epitopes on Tau. Furthermore GSK-3b associates with and is activated by presenilin-1 [29] ; mutations of presenilin-1 are directly linked to autosomal dominant AD [30] . Amyloid b-peptide, another molecular factor involved in AD [31] , leads to activation of GSK-3b when added to hippocampal neurons [32] . These observations, and others [23, 24] , place tau phosphorylation downstream of presenilins and amyloid b peptide, the two other main actors in AD.
CDK5 was initially identified on the basis of its sequence similarity with CDK1 [33] , later as tau protein kinase II [34±35] (reviewed in [36] ). It is activated by a 25-kDa protein [37±39], which derives, by proteolytic cleavage, from a 35-kDa precursor. It was recently shown that conversion of p35 to p25 leads to constitutive activation of CDK5 [40] , and alteration of its cellular localization and substrate specificity. CDK5/p25 expression in cultured primary neurons triggers apoptosis. These findings, as well as the accumulation of p25 [40] and increased CDK5 activity [41] in AD patients' brains, indicate that CDK5 activation may be involved in the cytoskeletal abnormalities and neuronal death observed in AD. Furthermore the phosphorylation of tau by GSK-3b on AD-specific sites is potentiated by CDK5 [42] . Both enzymes colocalize preferentially in neurofibrillary tangles [43] .
The involvement of PKA is demonstrated by the observation that sequential phosphorylation of tau by GSK-3b and PKA, at Thr212 and Ser214, respectively, generates the AD-specific AT100 cross-reacting epitope [44, 45] . Ser214 and Ser409 are AD-specific PKA phosphorylation sites [46] . CK1 may also be physiologically involved in the abnormal phosphorylation of tau in AD as it directly phosphorylates tau [47, 48] and also phosphorylates and activates CDK5 [49] . CK1d and : activities are elevated in AD relative to control hippocampus [48] .
The deregulation of kinases in many pathological situations has stimulated an active search for selective inhibitors (reviewed in [50±52]). Numerous potent chemical inhibitors of CDKs have been described (reviewed in [53±56]). These include olomoucine [57] , roscovitine [58] , purvalanol [59, 60] , flavopiridol [61] , butyrolactone [62] , indirubins [63] , hymenialdisine [64] , and the recently described family of paullones [65±67]. In contrast, no GSK-3 inhibitors have been reported besides lithium [68, 69] , which is not very potent and is unlikely to be very selective, and bisindolylmaleimide I and IV [70] , which are not very selective. Very recently, hymenialdisine [64] and indirubins (S. LeClerc [64] inhibit the in vivo phosphorylation of tau at AD-specific sites in cultured insect cells. Similarly, lithium inhibits the phosphorylation of tau in cultured neurons [72±74] .
We report here that paullones are very potent and selective inhibitors of GSK-3a/b and CDK5/p25 (IC 50 values in the 4±80 nm and 20±200 nm ranges, respectively). We show that alsterpaullone is able to inhibit the in vivo phosphorylation of tau at AD-specific sites by GSK-3b and the in vivo phosphorylation of DARPP-32 in isolated striatum slices by CDK5. By their dual specificity the paullones may thus constitute a lead family of compounds useful in the study and treatment of neurodegenerative disorders where tau is abnormally phosphorylated by GSK-3a/b and CDK5/p25.
M A T E R I A L S A N D M E T H O D S

Chemistry
Synthetic procedures for obtaining most of the paullones (see later) are provided in [66] . The synthesis of four new paullones are presented below. The synthesis of compounds K, N [75] , L [76] and M [77] (see later) have been previously reported.
2-Iodopaullone.
A slurry of phenylhydrazine (162 mg, 1.5 mmol) and 7-iodo-1H- [1] benzazepine-2,5(3H,4H)-dione [78] (301 mg, 1 mmol) in glacial acetic acid (10 mL) was stirred for 1 h at 70 8C. Concentrated sulfuric acid (0.1 mL) was added and stirring was continued for 1 h at 70 8C. After cooling to room temperature the mixture was poured into 5% aqueous sodium acetate solution (20 mL [79] (254 mg, 1 mmol), 4-nitrophenylhydrazine hydrochloride (284 mg, 1.5 mmol), and sodium acetate (123 mg, 1.5 mmol) were stirred in glacial acetic acid (10 mL) for 1 h at 70 8C. After cooling to room temperature, the mixture was poured into 5% aqueous sodium acetate solution (20 mL [66] (235 mg, 1 mmol), 4-nitrophenylhydrazine hydrochloride (569 mg, 3 mmol) and sodium acetate (246 mg, 3 mmol) were stirred in glacial acetic acid (10 mL) for 1 h at 70 8C. After cooling to room temperature, the mixture was poured into 5% aqueous sodium acetate solution (20 mL [66] (387 mg, 1 mmol) and copper(I) cyanide (179 mg, 2 mmol) were refluxed for 2 h in N-methyl-2-pyrrolidone (10 mL). After cooling to room temperature, water (10 mL) was added and the mixture was stirred for 15 min. The precipitate was filtered off with suction and subsequently stirred for 15 min in a mixture of water (10 mL) and ethylene diamine (2.5 mL). The precipitate was then filtered off with suction, washed with a 10% solution of sodium cyanide in water and crystallized from ethanol/toluene to yield 40% of colorless crystals, melting point . The GS-1 peptide (YRRAAVPPSPSLSRHSSPHQSpEDEEE) was synthesized by the Peptide Synthesis Unit, Institute of Biomolecular Sciences, University of Southampton, Southampton, UK.
AT-8, AT-180 and AT-100 antibodies were obtained from Innogenetics, SA (Ghent, Belgium), PHF-1 was a gift from P. Davies (Bronx Institute, NY) and K9JA was obtained from Dako (Hamburg, Germany). K9JA (a pan-tau antibody) recognizes all preparations containing tau. AT8, AT180 and PHF1 are specific for different phosphorylated SP or TP motifs, Ser202 and Thr205, Thr231 and Ser235 and Ser396 and Ser404, respectively (as numbered in htau40, the longest human tau isoform). 
Buffers
Kinase preparations and assays
Kinases activities were assayed in duplicates in Buffer A or C (unless otherwise stated), at 30 8C, at a final ATP concentration of 15 mm. The order of mixing of reagents was: buffers, substrate, enzyme, inhibitor. There was no preincubation at 30 8C. Addition of ATP was considered as time 0 of the incubation period. Assays were run under conditions where less than 5% of the radiolabelled phosphate was incorporated. Blank values were subtracted and activities calculated as pmol of phosphate incorporated for a 10-min incubation. The activities are usually expressed in percentage of the maximal activity, i.e. in the absence of inhibitors. Controls were performed with appropriate dilutions of dimethylsulfoxide. In a few cases phosphorylation of the substrate was assessed by autoradiography after SDS/PAGE (see below).
GSK-3b . GSK-3b was expressed in and purified from insect Sf9 cells [80] . It was assayed, following a 1/100 dilution in 1 mg BSA per mL 10 mm dithiothreitol, with 5 mL 40 mm GS-1 peptide as a substrate, in buffer A, in the presence of 15 mm [g- CDK1/cyclin B. CDK1/cyclin B was extracted in homogenization buffer from M phase starfish (Marthasterias glacialis) oocytes and purified by affinity chromatography on p9 CKShs1 -Sepharose beads, from which it was eluted by free p9
CKShs1 as previously described [58, 81] . The kinase activity was assayed in buffer C, with 1 mg histone H1 per mL, in the presence of 15 mm [g- ) in a final volume of 30 mL. After a 10-min incubation at 30 8C, 25 mL aliquots of supernatant were spotted onto P81 phosphocellulose papers and treated as described above.
CDK5/p25. CDK5/p25 was reconstituted by mixing equal amounts of recombinant mammalian CDK5 and p25 expressed in E. coli as GST (glutathione S-transferase) fusion proteins and purified by affinity chromatography on glutathione-agarose (vectors kindly provided by J. H. Wang, Dept. of Medical Chemistry, University of Calgary, Alberta, Canada) (p25 is a truncated version of the p35, the 35-kDa CDK5 activator). Its activity was assayed in buffer C as described for CDK1/ cyclin B.
The sources, purification methods and assay protocols of other enzymes (listed in Table 1 ) were previously described [57, 58] .
In vitro and in vivo Tau phosphorylation
Tau phosphorylation in vitro was performed using purified GSK-3b and recombinant human tau-32 (provided by M. Goedert, MRC Laboratory of Molecular Biology, Cambridge, UK) as a substrate. After 30 min incubation in the presence of various alsterpaullone concentrations, under the GSK-3b assay conditions described above, the kinase reaction was stopped by addition of Laemmli sample buffer. Tau was resolved by 10% SDS/PAGE and its phosphorylation level visualized by autoradiography.
Cells and viruses. Sf9 cells (InVitrogen, San Diego, CA, USA) were grown at 27 8C in monolayer culture Grace's medium (Gibco BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum, 50 mg gentamycin´mL 21 and 2.5 mg amphotericin´mL
21
. BaculoGold was obtained from PharMingen (San Diego, CA, USA), pVL1392 from InVitrogen.
Tau transfection. The gene for htau23, the shortest human tau isoform, was excised from the bacterial expression vector pNG2 [82] with XbaI and BamHI, and inserted into the baculovirus transfer vector pVL1392 cut with the same restriction endonucleases. The BaculoGold system was used to construct the tau baculovirus containing vector. The BaculoGold DNA is a modified type of baculovirus containing a lethal deletion. Cotransfection of the BaculoGold DNA with a complementing baculovirus transfer vector rescued the lethal deletion of this virus DNA and reconstituted viable virus particles carrying the htau23 coding sequence. Plasmid DNA used for transfections was purified using QIAGEN cartridges (Hilden, Germany). Sf9 cells grown in monolayers (2 Â 10 6 cells in a 60-mm cell culture dish) were cotransfected with baculovirus DNA (0.5 mg BaculoGold DNA) and with vector derivatives of pVL1392 (2 mg) using a calcium phosphate coprecipitation method. The presence of recombinant protein was examined in the infected cells 5 days postinfection by SDS/ PAGE and Western blotting. 
Tau Western blotting. Sf9 cells were infected with recombinant virus at a multiplicity of infection (MOI) of 1±5. Cell lysates were prepared in hypotonic lysis buffer (HLB). After 15 min centrifugation at 16 000 g, the supernatant was recovered and its NaCl concentration raised to 500 mm. It was then boiled for 10 min and recentrifuged at 16 000 g for 15 min. Proteins (3 mg) were resolved by SDS/PAGE, transferred to a poly(vinylidene difluoride) membrane, and Western blotted with the following antibodies: AT-8 (1 : 2000) , AT-180 (1 : 1000), AT-100 (1 : 1000), PHF-1 (1 : 600) and polyclonal anti-tau Ig K9JA. The immunostaining was visualized using the ECL chemiluminescence system (Amersham, Braunschweig, Germany).
In situ inhibition of CDK5 in the striatum
Adult mouse brain striatal slices were prepared using standard methodology [84] . Following equilibration in Krebs' bicarbonate buffer oxygenated with continuous aeration (95% O 2 /5% CO 2 ) slices were treated with various concentrations of alsterpaullone, or 10 mm roscovitine for 60 min, or left in Krebs' bicarbonate buffer for the same period of time. Slices were homogenized by sonication in boiling 1% SDS and 50 mm NaF. Protein concentrations were determined by the BCA method using a BSA standard curve. Equal amounts of protein (80 mg) were subjected to SDS/PAGE using a 15% acrylamide gel, electrophoretically transferred to nitrocellulose membrane and immunoblotted with a phosphorylation state-specific antibody that selectively detects DARPP-32 phosphorylated at Thr75 [85] .
R E S U L T S Paullones are potent inhibitors of GSK-3b and CDK5/p25
We have recently shown that several CDK inhibitors are also very potent inhibitors of GSK-3b [64] . This observation prompted us to evaluate the kinase selectivity of alsterpaullone, one of the most active CDK inhibitors of the recently described paullone family [66, 67] . Alsterpaullone was tested on a variety of highly purified kinases. Kinase activities were assayed with appropriate substrates and 15 mm ATP, in the presence of increasing concentrations of alsterpaullone. The IC 50 values obtained from the dose±response curves are shown in Table 1 . Most kinases tested were poorly or not inhibited (IC 50 . 10 mm). However, in addition to the previously reported effect on CDK1/cyclin B [66] , alsterpaullone was found to inhibit CDK2/cyclin A, CDK2/cyclin E, CDK5/p25 and GSK-3a/GSK-3b (IC 50 values of 15, 200, 40 and 4 nm, respectively) (Fig. 1) . Our collection of paullones ( Fig. 2; Table 2 ) was further evaluated for inhibition against GSK-3b, CDK5/p25 and CDK1/cyclin B. This confirms that paullones represent a family of potent GSK-3b and CDK inhibitors. There is a good correlation between the efficiency of the various paullones to inhibit GSK-3b and either CDK1 or CDK5. The efficiency of paullones towards CDK1 and CDK5 seem to be closely related. Alsterpaullone acts by competing with ATP binding at the catalytic site of GSK-3b
We have shown that paullones act on CDKs by competing with ATP for binding at the catalytic site [67] . Kinetic experiments demonstrate that alsterpaullone is also a competitor for ATP binding on GSK-3b (Fig. 3) . Recombinant GSK-3b was used throughout this study. As this preparation is likely to contain an unknown proportion of inactive, misfolded enzyme as well as some proteolytic degradation fragments, we feel it is inappropriate for a precise determination of the enzyme as K m and K i .
Alsterpaullone inhibits in vitro and in vivo phosphorylation of tau by GSK-3b
To confirm the inhibitory effects of alsterpaullone on GSK-3b activity (assessed with a peptide substrate) we also used a more physiological substrate, the microtubule-binding protein tau.
Bacterially expressed recombinant human tau can indeed be phosphorylated in vitro by GSK-3b and this phosphorylation is inhibited in a dose-dependent manner by alsterpaullone, with an IC 50 around 33 nm (Fig. 4A) . We next investigated the effect of alsterpaullone on the in vivo phosphorylation of human tau23 expressed in Sf9 cells (Fig. 4B ). Cells were left untreated (control), or exposed to 20 mm alsterpaullone or 20 mm aminopurvalanol. Aminopurvalanol is an excellent inhibitor of CDK5 (IC 50 : 0.020 mm) but not of GSK-3b (IC 50 . 10 mm). Htau23 was resolved by SDS/ PAGE followed by immunoblotting with various antibodies. Alsterpaullone clearly inhibits the phosphorylation of the PHF-1 epitope, Ser396 and Ser404. This is a very strong indication for inhibition of GSK3b; kinase in Sf9 cells, because the PHF-1 epitope represents the most prominent phosphorylation site of GSK-3b on tau protein, in contrast to other proline-directed kinases [86] . The disappearance of the AT100 epitope after treatment with alsterpaullone is another indication of inhibition of GSK-3b, because this antibody 
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Paullones inhibit GSK-3b and CDK5/p25 (Eur. J. Biochem. 267) 5987 Table 2 . Paullones inhibit GSK-3, CDK1/cyclin B, and CDK5/p25. GSK-3b and CDKs were assayed using the GS-1 peptide or histone H1 as substrates, respectively, with 15 mm ATP and in the presence of increasing concentrations of paullones. IC 50 s were obtained from the dose±response curves and are presented in mm. recognizes tau only when it is first phosphorylated at Thr212 by GSK-3b and then at Ser214 by PKA [44] . This reaction is highly specific for Alzheimer tau. The inhibition of the phosphorylation at the AT8 epitope (phosphorylated Ser202 and Thr205) may be due to the inhibition of either GSK-3b or CDK-like kinase because this epitope is a site for both kinases (but CDK-like kinases are more efficient). The weak inhibition of phosphorylation at the AT180 epitope (which includes phosphorylated Ser235 and Thr231) is an indication that alsterpaullone is a better inhibitor of GSK-3b than of CDKlike kinases in Sf9 cells because the AT180 epitope is primarily phosphorylated by CDK-like kinases [87] . Aminopurvalanol completely inhibits the phosphorylation of the AT-8 epitope and strongly decreases the AT180 epitope, indicating that it acts as an inhibitor of CDKs. This is confirmed by the lack of inhibition at PHF-1 epitope. On the other hand aminopurvalanol also inhibits AT100 phosphorylation, indicating some inhibition of GSK-3b or PKA, or, more likely, an indirect effect on these kinases.
Alsterpaullone inhibits DARPP-32 phosphorylation by CDK5 in vivo
Given the essential role of CDK5 in AD, we investigated the in vivo effects of alsterpaullone on CDK5 using the DARPP-32 protein, recently identified as a physiological substrate of CDK5/p25 [85] . When phosphorylated on Thr75 by this kinase, DARPP-32 becomes an inhibitor of PKA. In vivo phosphorylation on this site does not occur in p35 2 / 2 tissue [85] . To assess the ability of alsterpaullone to inhibit CDK5 in the brain, slices of striatum (the area of the brain expressing DARPP-32) were prepared and treated with different concentrations of alsterpaullone (Fig. 5) . Homogenates from these slices were then probed with a phosphorylation state-specific antibody that only detects DARPP-32 phosphorylated at Thr75. Alsterpaullone was able to inhibit phosphorylation of DARPP-32 in situ and in the same range of concentrations previously found to be effective for roscovitine [85] . The slight increase in DARPP-32 phosphorylation at 1 mm alsterpaullone is unlikely to be significant and probably reflects a sample loading variation. Fig. 4 . Alsterpaullone inhibits tau phosphorylation by GSK-3b in vitro and in vivo. (A) Bacterially expressed recombinant human tau was phosphorylated in vitro with GSK-3b in the presence of increasing alsterpaullone concentrations and resolved by SDS/PAGE, followed by autoradiography. (B) Sf 9 cells expressing htau23 were left untreated (control), or exposed to alsterpaullone or aminopurvalanol for 3 h. Cell lysates (3 mg htau23) were resolved by SDS/PAGE, stained with Coomassie blue or immunoblotted with various antibodies: K9JA (a pan-tau antibody) recognizes tau independently of phosphorylation; AT100 recognizes tau phosphorylated at Thr212 and Ser214, a highly specific reaction for Alzheimer tau; PHF-1 (phosphorylated Ser396/Ser404); AT8 (phosphorylated Ser202/ Thr205), AT180 (phosphorylated Thr231/Ser235). 
D I S C U S S I O N
Paullones inhibit GSK-3b and CDK5/p25
We have previously described the inhibition of CDKs by paullones [66, 67] . In this article we further investigate CDK5/ p25 inhibition and we also report that GSK-3a/b is an excellent target for paullones. We demonstrate that alsterpaullone is able to inhibit both enzymes in an in vivo situation. CDK5 is very closely related to CDK1 and CDK2 (73 and 75% identity at the amino-acid sequence level, respectively) [36] . GSK-3b is one of the evolutionary closest enzyme to the CDK family [2] . As with CDK1/cyclin B, alsterpaullone inhibits GSK-3b by competing with ATP for binding to the catalytic site (Fig. 3) . These observations support the idea that paullones bind to GSK-3b as they do to CDKs, although definitive comparison will require cocrystallization with each enzyme. GSK-3b appears to be even more sensitive to paullones than CDKs (see Table 2 ), but there are a few exceptions suggesting that it might be possible to obtain paullone derivatives selective for either GSK-3b or CDKs. With respect to the synthesis of compounds specific for either CDK1 or CDK5, CDK5 activity appears to be very sensitive to substitution at the 12 position [see: 9-Br-12-methoxycarbonylmethylpaullone, 9-Br-12-(2-hydroxyethyl)-paullone and 9-Br-12-methylpaullone in Table 2 ].
Selectivity of paullones
We have investigated the selectivity of kenpaullone [66, 67] and alsterpaullone (Table 1 ) using a wide set of purified kinases. Alsterpaullone is extremely selective for GSK-3a/b and CDK1/ 2/5. Some modest inhibitory activity on erk2 and PKA has been detected. All other kinases tested are insensitive. However, this kind of study only provides a very partial view of the range of cellular targets of paullones. As an alternative approach, we intend to purify and identify the paullone-binding proteins, from various tissues, by affinity chromatography on immobilized paullones. The model of paullone binding to CDK2 [88] provides precious information with respect to the orientation of the paullone rings within the ATP-binding pocket and the areas which are accessible to solvent. This is where a linker could be attached to tether the inhibitor to a solid matrix while maintaining free access of the inhibitor to its kinase targets. Using this approach with purvalanol, based on the CDK2/purvalanol crystal structure [59] , we have recently been able to identify the intracellular targets of purvalanol in a variety of cells and tissues [89] .
Antiproliferative properties of Paullones
The fact that paullones potently inhibit GSK-3b leads to a major question: what is the contribution of GSK-3a/b inhibition to the antimitotic properties of paullones? Does GSK-3b inhibition enhance or, on the contrary, does it reduce the cell cycle inhibitory effects of paullones? Would a paullone derivative devoid of GSK-3 a/b inhibitory properties be a more efficient antiproliferative agent? These are very important questions as their answer will orientate the optimization of paullones either towards highly CDK-or GSK-3a/b-selective compounds or towards dual-specificity agents.
The role of GSK-3b in regulating the cell division cycle is only starting to be evaluated. GSK-3b appears to participate to control cyclin D1 levels: (a) GSK-3b phosphorylates cyclin D1 on Thr286 and this leads to its redistribution from the nucleus to the cytoplasm and to its proteolytic degradation [11] . Inhibition of GSK-3b would thus be expected to result in cyclin D1 accumulation and favour cell cycle progression. (b) GSK-3b [in complex with the tumor suppressor protein adenomatous polyposis coli (APC) and axin] phosphorylates b-catenin, leading to its ubiquitin-dependent degradation. The failure of this degradation, resulting from mutant APC or b-catenin, is common in human colon cancer and melanoma. b-catenin associates with transcription factors of the LEF-1 family to activate the expression of specific genes, in particular the cyclin D1 gene [90, 91] . Inhibition of GSK-3b might thus be expected to lead to cyclin D1 accumulation.
In contrast, CDK inhibition is clearly expected to arrest the cell cycle at the G1/S and G2/M boundaries [53±56]. Thus inhibition of both CDKs and GSK-3a/b by paullones may turn out to create an`intracellular conflict of interest' which might only be solved by the induction of apoptosis. This is clearly a desired effect in cancer therapy. In this context, it was recently shown that overexpression of a catalytically active GSK-3b induces apoptosis, whereas a dominant-negative GSK-3b prevents apoptosis by inhibition of the PI3-kinase/Akt pathway [92] . Thus inhibition of GSK-3b by paullones is expected to inhibit apoptosis. GSK-3b inhibition may thus reduce or even mask therapeutically interesting properties of CDK inhibitors. Alternatively, GSK-3b inhibitors devoid of CDK inhibitory properties might be more efficient in cells.
Paullones inhibit tau phosphorylation: implication in Alzheimer's disease
Five recent discoveries have strongly stimulated the interest in understanding the causal link between tau hyperphosphorylation and the pathways responsible for AD: (a) the existence of tau mutations in AD-related diseases [23] (b) the functions of tau in regulating intracellular traffic along microtubules [93] (c) the accumulation of p25, a truncated form of p35, in the brains of patients with AD, which correlates with an increase in CDK5 kinase activity [40] (d) the apoptosis inducing properties of CDK5/p25 [40] and (e) the positioning of tau hyperphosphorylation downstream of the two other major AD actors, presenilins and amyloid b peptide [24] . Tau hyperphosphorylation is essentially carried out by two proline-directed kinases, GSK-3b and CDK5/p25, and to a lesser extent by PKA and casein kinase 1. These observations suggest that inhibition of CDK5 and GSK-3b can be expected to have a major impact on the abnormal hyperphosphorylation of tau observed in AD, and possibly also on the outcome of this disease. Paullones, and many of the previously reported CDK inhibitors, constitute lead compounds with great potential for the study and treatment of AD and other`taupathies'. This is further encouraged by several reports showing the up-regulation of a variety of cell cycle regulators (CDKs in particular) in brains of AD patients [94±96] (reviewed in [97] ), their involvement in b-amyloidinduced neuronal death [98, 99] , the protective effects of CDK inhibitors towards neuronal death [100±102] and the srole of GSK-3 in neuronal apoptosis [17, 103] .
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